Vered Bisker-Leib serves as the President & Chief Operating Officer of Compass Therapeutics, a clinical stage biopharmaceutical company focused on the discovery and development of antibodies and bispecifics for oncology and autoimmune indications. Dr. Bisker-Leib is also a board member of Ayala Pharmaceuticals.

Vered joined Compass in 2017 and assumed roles of increasing responsibility across business development, finance and operations. As the Chief Operating Office and Chief Financial Officer of the company, she identified and led the acquisition of TRIGR Therapeutics in a $50 million stock-for-stock transaction, adding a novel bispecific antibody to Compass pipeline, which has become Compass’ flagship program (CTX-009). She also led the transitioning of the company from private to a Nasdaq-trading-company via two financing events that generated more than $190M in total funding. Prior to Compass, Vered was an Executive-In-Residence with Atlas Ventures, where she advised Atlas portfolio companies. Previously, as the Chief Business Officer of Cydan, a biotech accelerator, she co-founded biotech companies focused on therapies addressing rare diseases. Prior to joining Cydan, Vered was a member of Bristol-Myers Squibb’s strategic transactions group where she assumed roles of increasing responsibility across five therapeutic areas, most recently as an Executive Director and Global Head of business development for the Cardiovascular and Metabolic franchises.

Vered concurrently earned her PhD in Chemical Engineering and MBA from the University of Massachusetts, Amherst, where she was a Lois Pope MBA Scholar. She has a BSc in Chemical Engineering from the Israel Institute of Technology, Haifa.